Progress and challenges towards targeted delivery of cancer therapeutics

Daniel Rosenblum; Nitin Joshi; Wei Tao; Jeffrey M. Karp; Dan Peer

doi:10.1038/s41467-018-03705-y

Progress and challenges towards targeted delivery of cancer therapeutics

Daniel Rosenblum, Nitin Joshi, Wei Tao, Jeffrey M. Karp, Dan Peer

Houston Methodist

Research output: Contribution to journal › Review article › peer-review

1950 Scopus citations

Abstract

Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.

Original language	English (US)
Article number	1410
Pages (from-to)	1410
Journal	Nature Communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-03705-y
State	Published - Apr 12 2018

Keywords

Antineoplastic Agents/chemistry
Drug Approval/legislation & jurisprudence
Drug Carriers
Drug Compounding/methods
Humans
Molecular Targeted Therapy/methods
Nanomedicine/methods
Nanoparticles/administration & dosage
Neoplasms/drug therapy

ASJC Scopus subject areas

General Physics and Astronomy
General Chemistry
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41467-018-03705-y

Cite this

@article{caffe4d9670844648964e09654eca785,

title = "Progress and challenges towards targeted delivery of cancer therapeutics",

abstract = "Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.",

keywords = "Antineoplastic Agents/chemistry, Drug Approval/legislation \& jurisprudence, Drug Carriers, Drug Compounding/methods, Humans, Molecular Targeted Therapy/methods, Nanomedicine/methods, Nanoparticles/administration \& dosage, Neoplasms/drug therapy",

author = "Daniel Rosenblum and Nitin Joshi and Wei Tao and Karp, \{Jeffrey M.\} and Dan Peer",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = apr,

day = "12",

doi = "10.1038/s41467-018-03705-y",

language = "English (US)",

volume = "9",

pages = "1410",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Progress and challenges towards targeted delivery of cancer therapeutics

AU - Rosenblum, Daniel

AU - Joshi, Nitin

AU - Tao, Wei

AU - Karp, Jeffrey M.

AU - Peer, Dan

PY - 2018/4/12

Y1 - 2018/4/12

N2 - Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.

AB - Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.

KW - Antineoplastic Agents/chemistry

KW - Drug Approval/legislation & jurisprudence

KW - Drug Carriers

KW - Drug Compounding/methods

KW - Humans

KW - Molecular Targeted Therapy/methods

KW - Nanomedicine/methods

KW - Nanoparticles/administration & dosage

KW - Neoplasms/drug therapy

UR - https://www.scopus.com/pages/publications/85045523734

UR - https://www.scopus.com/inward/citedby.url?scp=85045523734&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-03705-y

DO - 10.1038/s41467-018-03705-y

M3 - Review article

C2 - 29650952

AN - SCOPUS:85045523734

SN - 2041-1723

VL - 9

SP - 1410

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 1410

ER -

Progress and challenges towards targeted delivery of cancer therapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this